New US patent for SBECD purification by CycloLab
The status of US patent application 17/344,217 (“Purification of sulfobutylated cyclodextrins with specific ion exchange resins” by CycloLab, Hungary) was
Author: István Puskás
research chemist
Remdesivir- Dexolve formulation in the space – a book of NASA
In the annual report of NASA there is a great recognition of benefits of cyclodextrin technology even in space chemistry.
Low sulfur biodiesel produced from sewage enabled by beta-cyclodextrin
Emeritus Professor Richard Parnas and his group at University of Connecticut Department of Chemical and Biomolecular Engineering developed a technology
May a novel alfa-cyclodextrin derivative be applied effectively to capture atmospheric methane?
Researchers at the University of Copenhagen’s Faculty of Science received a research grant to find out. Methane gas is 86
Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice
Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of
First Patient Enrolled in Phase 1 Study of Midatech’s Panobinostat / HPBCD (MTX-110) for Recurrent Glioblastoma
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announced on 14 November
Australian company pioneering Cavadextrin for regression of atherosclerosis
Newsmaker, the Australian Press Release Distribution Service has published the news on “An Australian pioneering a medical breakthrough treatment that
Eye drops containing methyl BCD as active – clinical trial
Cloudbreak Therapeutics, LLC has sponsored a multicenter, randomized, double-masked, vehicle-controlled, parallel group study using CBT-008 (buffered solution of methyl BCD)
MIT scientists filed patent for HPBCD treatment in Alzheimer’s disease
Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent
Cyclodextrin containing biocidal banknotes
GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH, a company founded 170 years ago, has filed a patent application on papers with biocidal properties